Everything below concerns metabolite. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
==== Gas chromatography ==== One case study monitored the dehydrogenation of propane to propene using micro-GC. Reproducibility for the experiment was high. The study found that the catalyst (Cr/Al2O3) activity increased to a sustained maximum of 10% after 28 minutes — an industrially useful insight into the working stability of a catalyst.
=== Pharmacokinetics === Steady-state levels of clascoterone occur within 5 days of twice daily administration. At a dosage of 6 g clascoterone cream applied twice daily, maximal circulating levels of clascoterone were 4.5 ± 2.9 ng/mL, area-under-the-curve levels over the dosing interval were 37.1 ± 22.3 h*ng/mL, and average circulating levels of clascoterone were 3.1 ± 1.9 ng/mL. In rodents, clascoterone has been found to possess strong local antiandrogenic activity, but negligible systemic antiandrogenic activity when administered via subcutaneous injection. Along these lines, the medication is not progonadotropic in animals. The plasma protein binding of clascoterone is 84 to 89% regardless of concentration. Clascoterone is rapidly hydrolyzed into cortexolone (11-deoxycortisol) and this compound is a possible primary metabolite of clascoterone based on in-vitro studies in human liver cells. During treatment with clascoterone, cortexolone levels were detectable and generally below or near the low limit of quantification (0.5 ng/mL). Clascoterone may also produce other metabolites, including conjugates. The elimination of clascoterone has not been fully characterized in humans.
“childhood chronic disease crisis.” Its main focus is on how diet, environmental chemicals, lack of physical activity, stress, and what it calls “overmedicalization” contribute to rising rates of obesity, diabetes, and other chronic conditions in children. In February 2026, Trump announced TrumpRx as a discount prescription drug service In November 2025 with Novo Nordisk and Eli Lilly to slash prices on Ozempic (semaglutide) and similar GLP-1 drugs like Wegovy and Zepbound. The agreement cuts Ozempic from over $1,000 monthly to $199-$350 via TrumpRx for self-pay patients, with Medicare/Medicaid at $245.
=== Two-dimensional chromatography === Two-dimensional chromatography represents the most thorough and rigorous approach to evaluation of the proteome. While previously accepted approaches have utilized elution mode chromatographic approaches such as cation exchange to reversed phase HPLC, yields are typically very low requiring analytical sensitivities in the picomolar to femtomolar range. As displacement chromatography offers the advantage of concentration of trace components, two dimensional chromatography utilizing displacement rather than elution mode in the upstream chromatography step represents a potentially powerful tool for analysis of trace components, modifications, and identification of minor expressed components of the proteome.
Sources: en.wikipedia.org
Thermal noise results from the motion of charge carriers (usually electrons) in an electrical circuit generated by their thermal motion. Thermal noise is white noise, meaning that the power spectral density is constant throughout the frequency spectrum. The root mean square value of the thermal noise in a resistor is given by
Albany is the home of the main campus of a two-year junior college called Linn-Benton Community College, which was established in 1966. The college offers certificates and associate degrees and has many transfer and dual enrollment programs with OSU. LBCC offers 47 areas of study and programs, serves over 18,000 full- and part-time students and is supported financially through tuition, property taxes and the State of Oregon. The Albany area has also been served since 1979 by the Greater Albany Public School District, including West Albany High School, and South Albany High School, which have a combined enrollment of approximately 2,700 students. Albany is also served by Albany Options School as an alternative to traditional school for grades 6 through 12. In total Greater Albany Public School District serves roughly 8,900 students throughout its 23 different schools. Along with the K-12 schools Albany also offers student services at the Maple Lawn Preschool.
Dershowitz's campaign to acquit von Bülow was assisted by Jim Cramer and future New York attorney general and governor Eliot Spitzer, who were then Harvard Law School students. Dershowitz and his team focused on the discovery of the bag containing the syringes and insulin. Sunny's family had hired a private investigator to look into her coma. The private investigator, Edwin Lambert (an associate of the Bülows' lawyer Richard Kuh), was told by several family members and a maid that Claus had recently been seen locking a closet in the Newport home that previously was always kept open. The family hired a locksmith to drive to the mansion, with the intention of picking the closet lock to find what the closet contained. They had lied to the locksmith and told him that one of them owned the house. When the three arrived, the locksmith insisted that they try again to find the key, and after some searching, Kuh found a key in von Bülow's desk that unlocked the closet. At this point, according to the three men in the original interviews, the locksmith was paid for the trip and left before the closet was actually opened, although the men would later recant that version and insist that the locksmith was present when they entered the closet. It was in the closet that the main evidence against von Bülow was found. In 1984, the two convictions from the first trial were reversed by the Rhode Island Supreme Court. In 1985, after a second trial, von Bülow was found not guilty on all charges.
=== The discovery of copper-histidine in human blood and invention of Menkes disease treatment === Sarkar discovered copper-histidine in human blood in 1966 and recognized it as a biological form by which copper, an essential element to sustain life, is transported in blood. In 1976, Sarkar proposed that a baby with Menkes disease receive copper-histidine via subcutaneous injection. This was the world's first Menkes patient to receive copper-histidine therapy. Children with this disease are now living longer and reaching adulthood with copper-histidine treatment. Sarkar did not patent copper-histidine; he intended that it be readily available to Menkes patients at a reasonable cost. The formulation and detailed compounding procedure for the preparation of copper-histidine is freely available by SickKids Pharmacy to physicians and hospital pharmacies around the world upon request. Sarkar also helped make copper-histidine formulation for Menkes disease in other countries, including the NIH Clinical Center, Bethesda, Maryland, USA, India, and Mexico.
== In popular culture == Deceit – 2021 British television mini-series The Witness – 2026 Netflix series The Murder of Rachel Nickell - Netflix documentary The Wimbledon Boys - 2023 fiction book by Luis Domingues
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.